title: Local low-dose IL-2 therapy.
abstract: Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.
authors.affiliation: Department of Cell Biology, Utrecht University, The Netherlands. w.denotter@pobox.accu.uu.nl
authors.forename: W
authors.initials: W
authors.lastname: Den Otter
authors.forename: L
authors.initials: L
authors.lastname: Balemans
authors.forename: J J
authors.initials: JJ
authors.lastname: Battermann
authors.forename: M R
authors.initials: MR
authors.lastname: Bernsen
authors.forename: J A
authors.initials: JA
authors.lastname: Cadee
authors.forename: Z
authors.initials: Z
authors.lastname: Dobrowolski
authors.forename: L A
authors.initials: LA
authors.lastname: Everse
authors.forename: L
authors.initials: L
authors.lastname: Fiszer-Maliszewska
authors.forename: R
authors.initials: R
authors.lastname: Gavhumende
authors.forename: J W
authors.initials: JW
authors.lastname: De Groot
authors.forename: K
authors.initials: K
authors.lastname: De Groot
authors.forename: W E
authors.initials: WE
authors.lastname: Hennink
authors.forename: F W
authors.initials: FW
authors.lastname: Hill
authors.forename: I
authors.initials: I
authors.lastname: Jurgenliemp-Schulz
authors.forename: W R
authors.initials: WR
authors.lastname: Klein
authors.forename: J W
authors.initials: JW
authors.lastname: Koten
authors.forename: R A
authors.initials: RA
authors.lastname: Maas
authors.forename: P
authors.initials: P
authors.lastname: Steerenberg
authors.forename: R
authors.initials: R
authors.lastname: Stewart
authors.forename: M
authors.initials: M
authors.lastname: Zembala
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D002417:Cattle; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005134:Eye Neoplasms / Q000628:therapy; D006801:Humans; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage*; D008223:Lymphoma / Q000628:therapy; D008325:Mammary Neoplasms, Experimental / Q000628:therapy; D012515:Mast-Cell Sarcoma / Q000628:therapy; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000628:therapy
chemical_list: D007376:Interleukin-2; D002945:Cisplatin